Study guide
9.2 Postpartum Hormonal Contraception & Intrauterine Devices
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
9.2 Postpartum Hormonal Contraception & Intrauterine Devices
Key Takeaways Explain This Topic AI
Combined hormonal contraception is Category 4 before 21 days, Category 2 from 21 to 42 days without VTE risk factors, and Category 3 from 21 to 42 days for breastfeeding patients or those with VTE risk factors.
Norethindrone progestin-only pills require dosing within a 3-hour window with 48 hours of backup if late, while drospirenone pills allow a 24-hour window.
DMPA is given every 13 weeks with a 2-week grace period, and return of fertility averages 9 to 10 months after discontinuation.
Immediate postplacental IUD insertion within 10 minutes of placental delivery has a 10 to 15 percent expulsion rate versus 2 to 5 percent for delayed interval placement.
Immediate postpartum LARC is recommended despite higher expulsion because 40 to 50 percent of patients never return for the postpartum visit; puerperal sepsis or ongoing hemorrhage makes insertion Category 4.
Last updated: September 2026
Combined Hormonal Contraception (CHCs) & Postpartum Thromboembolism
Combined Hormonal Contraceptives (oral contraceptive pills, transdermal norelgestromin/ethinyl estradiol patch, and etonogestrel/ethinyl estradiol vaginal ring) carry significant puerperal restrictions due to two distinct pharmacological risks:
Venous Thromboembolism (VTE) Risk: The postpartum state is an independent, profound prothrombotic state. Baseline VTE risk is 20- to 80-fold higher than in non-pregnant, non-postpartum individuals, peaking sharply in the first 21 days. Exogenous estrogens stimulate hepatic production of fibrinogen, factor VII, factor VIII, and factor X, while suppressing endogenous protein S and antithrombin III. Introducing exogenous estrogen during the first 3 weeks compounds this hypercoagulability, creating an unacceptable risk of deep vein thrombosis, pulmonary embolism, and cerebral venous thrombosis.
Suppression of Lactogenesis: Exogenous ethinyl estradiol competitively antagonizes prolactin receptors and impairs mammary alveolar responsiveness, particularly during Lactogenesis II (days 2–5). This can severely curtail milk supply and shorten overall breastfeeding duration.
Clinical Prescribing Algorithm for CHCs
<21 Days Postpartum: Category 4 (Absolute Contraindication) for ALL women, regardless of infant feeding choice.
21 to 42 Days Postpartum:
Non-breastfeeding women WITHOUT VTE risk factors: Category 2 (Generally safe).
Non-breastfeeding women WITH VTE risk factors: Category 3 (Risks outweigh benefits). Risk factors include: age ≥35 years, pre-pregnancy BMI ≥30 kg/m², cesarean delivery, postpartum hemorrhage, preeclampsia, smoking, immobility, or known inherited thrombophilia.
Breastfeeding women: Category 3 (due to potential suppression of milk volume).
>42 Days (>6 Weeks) Postpartum: Category 1 (Unrestricted, unless preexisting medical contraindications exist).
Progestin-Only Methods: Immediate Postpartum Safety
Unlike estrogens, progestins do not alter hepatic synthesis of procoagulant proteins and do not increase VTE risk. Furthermore, extensive clinical trials confirm that progestins do not impair Lactogenesis II or III, do not diminish milk volume, and do not affect infant growth or neurodevelopment.
1. Progestin-Only Pills (POPs)
Formulations:
Norethindrone (0.35 mg daily): Thickens cervical mucus within 2 to 4 hours of ingestion and suppresses ovulation in ~50% of cycles. Strict Adherence Window: Must be taken at the exact same time every day. If taken more than 3 hours late , a backup barrier method (e.g., condoms) is mandatory for 48 hours .
Drospirenone (4 mg daily, Slynd): Suppresses ovulation consistently; features a 24-hour missed pill window , providing greater user forgiveness.
Timing: Can be initiated immediately postpartum on Day 1 (US MEC Category 1).
2. Depot Medroxyprogesterone Acetate (DMPA / Depo-Provera)
Dosing: 150 mg deep intramuscular injection (gluteal or deltoid) or 104 mg subcutaneous injection every 13 weeks (with a 2-week grace period up to 15 weeks).
Clinical Advantages: Highly effective, user-independent, private, and compatible with antiepileptic enzyme-inducing drugs.
Counseling Pearls: Common side effects include unpredictable irregular spotting during the first 6 to 12 months, eventual amenorrhea (in 50% by 1 year), transient loss of bone mineral density (reversible upon cessation), and potential delay in return of fertility averaging 9 to 10 months after discontinuation.
3. Etonogestrel Subdermal Implant (Nexplanon)
Profile: A single 4-cm rod containing 68 mg of etonogestrel placed subdermally in the inner non-dominant upper arm. Provides >99.9% contraceptive efficacy for up to 3 to 5 years by suppressing ovulation and thickening cervical mucus.
Immediate Postpartum Placement: Highly recommended by ACOG and ACNM for insertion prior to hospital discharge . Immediate placement eliminates barriers to outpatient follow-up and does not impair lactogenesis. The primary side effect is unpredictable, irregular bleeding patterns, which requires thorough anticipatory counseling.
Intrauterine Devices (IUDs): Protocols & Expulsion Dynamics
Intrauterine contraception—including the copper T380A IUD (ParaGard; hormone-free, 10–12 years) and levonorgestrel-releasing IUDs (LNG-52 mg [Mirena, Liletta; 8 years], LNG-19.5 mg [Kyleena; 5 years])—represents the most effective reversible contraceptive modality. [ Postpartum IUD Insertion Timing Windows ]
- │
- ┌──────────────────────────────┼──────────────────────────────┐
- ▼ ▼ ▼
- [ Immediate Postplacental ] [ Early Postpartum ] [ Delayed Interval ]
- Within 10 min of placenta 10 min to 48 hours ≥4 to 6 weeks
- Vaginal or Cesarean birth Prior to hospital discharge Full uterine involution
- Expulsion rate: ~10%–15% Expulsion rate: ~10%–15% Expulsion rate: ~2%–5%
- Category 1 / 2 Category 1 / 2 Category 1
- Timing Categories & Expulsion Kinetics
Immediate Postplacental Insertion: Placed within 10 minutes of placental expulsion (during a vaginal birth or at the time of cesarean hysterotomy closure).
Early Postpartum Insertion: Placed between 10 minutes and 48 hours postpartum prior to discharge.
Intermediate Window (48 Hours to 4 Weeks): Relative contraindication ( US MEC Category 2 or 3 ). During this period, the rapidly involuting myometrium is soft, friable, and vascular, leading to heightened risks of uterine perforation and high expulsion rates. Insertion is generally deferred until ≥4 weeks.
Delayed Interval Insertion: Placed at or after 4 to 6 weeks postpartum , once uterine involution is near completion.
The Expulsion vs. Access Paradigm
Expulsion Risk: Immediate postplacental and early postpartum IUD placement carries a clinically recognized expulsion rate of approximately 10% to 15% (compared to 2% to 5% for delayed interval placement).
Clinical Midwifery Rationale: Despite higher expulsion rates, major clinical guidelines (ACOG, ACNM, CDC, WHO) strongly advocate for immediate postpartum LARC. In standard obstetric populations, up to 40% to 50% of postpartum individuals never return for their 6-week postpartum visit , leaving them at imminent risk for rapid repeat unintended pregnancy. Providing IUD insertion before discharge ensures 100% access, immediate contraception, and high overall 12-month continuation rates (>80%). Patients are counseled on expulsion signs and scheduled for string checks.
Absolute Contraindication: Puerperal sepsis, chorioamnionitis, or active, unexplained postpartum hemorrhage is US MEC Category 4 (Strictly Contraindicated) .